What is in GLOW?
GLOW contains GHK-Cu, BPC-157, and TB-500. Products sold as GLOW usually list GHK-Cu, BPC-157, and TB-500 in one vial, but the ratio and total amount differ from seller to seller, and some labels add other ingredients. Research-chemical products are not made or tested to a drug standard, so what a vial actually contains is not verified. PeptideAgent does not name or link sellers.
Also searched as: Glow peptide blend; GLOW blend; GHK-Cu, BPC-157, and TB-500 blend.
| Ingredient | Why it is in the mix | Status (alone) |
|---|---|---|
| GHK-Cu | Sold as the skin, collagen, and hair component, based mainly on topical cosmetic studies. |
|
| BPC-157 | Sold as the tissue healing and gut component, based on rodent studies. |
|
| TB-500 | Sold as the recovery and wound repair component, based on animal studies of full-length thymosin beta-4, a different substance from TB-500. |
|
Grades and statuses come from each peptide's own record and update with it. Grades follow the methodology.
Why are these peptides combined in GLOW?
The pitch for GLOW is that three repair signals add up: GHK-Cu for collagen and skin remodeling, BPC-157 for blood vessel growth and soft tissue healing, and TB-500 for cell migration and wound closure. Each claim traces back to laboratory and animal work on a single substance, not to any study of the three together, and the TB-500 claim traces back to work on full-length thymosin beta-4, which FDA says is not the same substance as TB-500.
The skin half of the story comes from topical GHK-Cu, where small cosmetic studies reported firmer skin and fewer fine lines. The healing half comes from rodent tendon, muscle, and wound models of BPC-157 and of full-length thymosin beta-4, the 43 amino acid protein that TB-500 is a 7 amino acid fragment of. A 2026 review of peptides marketed for injury recovery found that many unapproved peptides look favorable in animal models while rigorous human safety data remain scarce. [3] [4] [7] [9] [17]
Has GLOW been studied?
No published study has tested GLOW, or any combination of GHK-Cu, BPC-157, and TB-500, in humans or animals. PubMed indexes no trial of the three together as of the last verification date.
The single ingredients do not close that gap. There is no human trial of injected GHK-Cu for any indication; its human data are topical: small cosmetic studies and one small randomized trial after laser resurfacing that found no difference in redness, wrinkles, or skin quality by blinded assessment. A 2025 systematic review of BPC-157 found 35 preclinical studies and one small retrospective human report, and no clinical safety data. No human study of TB-500 itself has been identified. The small phase 1 and phase 2 human trials often cited for it (IV safety, eye drops for dry eye, a topical form for skin ulcers) tested full-length thymosin beta-4, which FDA says is not the same substance as TB-500.
Mixing peptides in one vial also raises questions nobody has studied: whether they stay stable together, whether they interact, and whether their side effects add up. [4] [5] [8] [9] [14] [15] [16] [17]
What each ingredient has shown alone
- GHK-Cu (human RCT evidence). Copper binding peptide used in skin cosmetics; one small randomized topical trial found no objective benefit. Injectable form is unapproved and untested.
- BPC-157 (animal-only evidence). A 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a draft HHS compounding policy from October 2026.
- TB-500 (animal-only evidence). Synthetic 7 amino acid fragment of thymosin beta-4. No human study of TB-500 itself; the human trials used the full-length protein. WADA banned.
GLOW results and before and after claims
Searches for GLOW before and after photos are common, but photos are not evidence. They are not controlled for lighting, skin care, weight change, time, or selection of the best results, and the product in the photo is not verified.
The measured human outcomes closest to the GLOW claims come from topical GHK-Cu cosmetic studies, which reported tighter skin, better elasticity, and fewer fine lines after weeks of daily application. Those studies are small, many were run or summarized by the peptide's discoverer, and none used an injection. The one small randomized trial of topical GHK-Cu, after laser resurfacing, found no difference in redness, wrinkles, or skin quality by blinded assessment. No human study has measured skin, hair, or healing outcomes after injecting GLOW or its peptides.
A 2026 sports medicine review also names the placebo effect as a driver of perceived peptide results and notes that social media amplifies it. Until a controlled trial exists, reported results for GLOW are anecdotes. [4] [8] [9] [16]
What are the side effects of GLOW?
There is no safety study of GLOW. Its risks are the unknowns of each ingredient plus the unknowns of the product: a systematic review found no clinical safety data at all for BPC-157, and there are no systematic human safety data for injected GHK-Cu or TB-500.
The problems most often reported with injected peptides are injection site pain, redness, and irritation. Reviews also raise a theoretical concern that peptides which promote new blood vessel growth and cell migration could affect existing tumors. That has not been shown in humans, and it has not been ruled out.
Product risk may be larger than drug risk. The BPC-157 systematic review warns that adverse effects are possible from unregulated manufacturing and contamination, and a vial of three peptides multiplies the chances of a wrong amount or a wrong ingredient. [3] [6] [8] [9]
Reported for each ingredient
From each peptide's record. These were reported for the peptide alone, not for the blend. Absence of data is not evidence of safety.
| Ingredient | Reported side effects and safety notes |
|---|---|
| GHK-Cu |
|
| BPC-157 |
|
| TB-500 |
|
Is GLOW legal?
A blend inherits the strictest status among its ingredients, because a mixed product is only as lawful as its least lawful component. For GLOW that is GHK-Cu, BPC-157, and TB-500: no federal basis to compound. At least one ingredient is not FDA approved and not on the 503A bulks list, so a licensed pharmacy has no federal basis to compound the mix.
- GHK-Cu regulatory timeline (Nomination withdrawn)
- BPC-157 regulatory timeline (HHS interim policy (draft))
- TB-500 regulatory timeline (HHS interim policy (draft))
Why blends like this are sold as research chemicals
A drug for human use in the United States has to be FDA approved or lawfully compounded by a licensed pharmacy for a named patient under a prescription. This blend can be neither, so vials sold under its name carry labels such as “for research use only” or “not for human consumption”. That label does not make a product lawful to inject, and it means no one has checked the vial for identity, purity, sterility, or amount. [11]
WADA status
BPC-157 and TB-500 are prohibited at all times on the WADA list, so any product containing them is prohibited for athletes subject to anti-doping testing.
State rules: peptide laws by state. All FDA actions: regulatory tracker.
What does GLOW cost, and what can a provider lawfully offer?
There is no lawful compounded price for GLOW, because there is no federal basis to compound it. A 503A pharmacy may compound from a bulk drug substance only if the substance has a USP or NF monograph, is a component of an FDA approved drug, or appears on the 503A bulks list. Injectable GHK-Cu meets none of those conditions: its nomination was withdrawn, it is not on the bulks list, and it was not reviewed by the Pharmacy Compounding Advisory Committee in July 2026. A mix is only as eligible as its least eligible ingredient.
BPC-157 and TB-500 are not on the 503A bulks list either. On October 28, 2026, HHS released a draft enforcement discretion policy for six peptides, including BPC-157 and TB-500, that covers only single-ingredient compounded products made under strict conditions. Blends and stacks such as GLOW are not covered, even though two of its ingredients are covered on their own. The policy is a draft, not an FDA approval, and does not add either peptide to the bulks list. At the July 2026 advisory committee meeting, FDA's drug center recommended against listing each and the committee voted in favor, according to Appendix B of the HHS policy.
Topical GHK-Cu is different. Cosmetic creams and serums are lawfully sold without FDA premarket approval as long as they make no drug claims, and that is also the form with the human skin data. Clinic and research-chemical prices for GLOW vials are not a lawful price, and research-chemical products are labeled not for human use. [10] [11] [12] [19] [20]
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [21] [22] [23]
Being offered does not change the legal status of GLOW. GHK-Cu, BPC-157, and TB-500 are not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound the mix. [11] [24]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [21] [24] [25] [26] [27] [28]
What that means for you
- A pharmacy that compounds GLOW is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [21] [25]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [28]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [29]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [30] [31]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [24]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, GLOW contains at least one ingredient that is prohibited under the WADA Prohibited List. [13]
If you're going ahead anyway
These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound GLOW, with or without a prescription. [11]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [32] [33] [34]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [23] [34] [35]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [28] [36] [37] [38] [39] [40]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [28]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [32]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [23]
- Pharmacy: Is this made for me on a prescription written in my name? [35]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [23] [34]
- Prescriber: What is the legal basis for a pharmacy to compound GLOW? Is it FDA approved or on the 503A bulks list? [11] [28]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [23]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [29]
Compare the ingredients
- BPC-157 vs GHK-Cu
- BPC-157 vs TB-500
- TB-500 vs GHK-Cu
- BPC-157 vs ARA-290 (cibinetide)
- BPC-157 vs KPV
- Thymosin alpha-1 vs TB-500
Blends that share an ingredient
- KLOW: KLOW is GLOW plus KPV: GHK-Cu, BPC-157, TB-500, and KPV in one vial. No study has tested it, and HHS's draft policy excludes blends.
- Wolverine stack: The Wolverine stack pairs BPC-157 and TB-500 for injury recovery. No study has tested the pair, and HHS's draft peptide policy does not cover blends.
Frequently asked questions
What is GLOW peptide?
GLOW is a nickname for an injectable mix of GHK-Cu, BPC-157, and TB-500 sold online and by some clinics for skin, hair, and healing. It is not an approved drug, no study has tested the blend, and it has no federal basis to be compounded. [9] [11]
Does GLOW peptide work?
Nobody knows, because it has never been tested. Topical GHK-Cu has small cosmetic studies and one small randomized trial that found no objective benefit, BPC-157 has mostly animal data, and TB-500 has no human study: the trials often cited for it tested full-length thymosin beta-4, a different substance. None of that shows what the injected mix does in people. [4] [5] [8] [16] [17]
Is GLOW peptide legal?
Not as a drug for human use. Injectable GHK-Cu has no federal basis to be compounded, and HHS's October 28, 2026 draft policy covers BPC-157 and TB-500 only as single-ingredient compounded products, not mixes like GLOW. Products labeled for research use are unapproved drugs when sold for human use. [11] [18] [20]
Are there real GLOW peptide before and after results?
There are no controlled before and after results for GLOW. Photos online are uncontrolled and the product in them is unverified. The only measured skin outcomes come from small studies of topical GHK-Cu, not the injected blend. [4] [9]
What are the side effects of GLOW peptide?
No study has recorded them. Injection site pain and irritation are reported anecdotally, none of the three injected peptides has systematic human safety data, and contamination is a risk with unregulated products. [8] [9]
Is GLOW allowed for tested athletes?
No. BPC-157 is prohibited at all times under WADA section S0 and TB-500 under section S2, so a product containing them is prohibited. GHK-Cu's own WADA status is unclear. [13]
What is the difference between GLOW and KLOW?
KLOW is GLOW plus KPV, a small anti-inflammatory fragment of alpha-MSH with mouse colitis data and no human trial. Neither blend has been studied, so neither can be called better. [1] [2]
Is there a lawful alternative to GLOW?
For skin, topical GHK-Cu cosmetics are lawful and are the form with human data. For an injury or a skin condition, a licensed clinician can discuss treatments with trial evidence. PeptideAgent does not recommend any peptide. [4] [10]
From the blog
- GLOW peptide before and after: what the evidence shows
No study has measured GLOW peptide before and after results. What each ingredient's human evidence shows for skin and hair, documented side effects, and the blend's legal status.
- Klow vs Glow peptide: what KPV adds and what is known
Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.
- Copper peptides for hair: what the studies show
Does GHK-Cu help with hair growth? Copper peptides enlarge hair follicles in lab and mouse studies, but no randomized trial of GHK-Cu alone for hair loss exists. How they compare with minoxidil.
- Peptide before and after: trial results vs marketing photos
Measured peptide before and after results: GLP-1 weight change, tesamorelin visceral fat, and regain after stopping, compared with Glow, GHK-Cu, BPC-157, and Wolverine claims.
- Topical vs injectable GHK-Cu: what the evidence shows
Topical GHK-Cu has small skin studies and is a lawful cosmetic. Injectable GHK-Cu has no human trial and is not on the 503A bulks list. Evidence, absorption, safety, and legality compared.
- Peptides for women, ranked by human evidence
GLP-1 drugs, teriparatide, abaloparatide, and Vyleesi (PT-141) have real trials in women. Kisspeptin is research-only and GHK-Cu rests on small skin studies. The ranking and legal status.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008PubMed 18092346, 2008
- [2]Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008PubMed 18061177, 2008
- [3]Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012PubMed 22074294, 2012
- [4]Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015PubMed 26236730, 2015
- [5]Sosne G et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial. Clin Ophthalmol 2015PubMed 26056426, 2015
- [6]Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018PubMed 29986520, 2018
- [7]Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell Tissue Res 2019)PubMed 30915550, 2019
- [8]Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025PubMed 40756949, 2025
- [9]Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med 2026PubMed 41966639, 2026
- [10]FDA: Is it a cosmetic, a drug, or both? (or is it soap?)FDA, 2024
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). GLOW peptide: what is in it and does it work?. https://peptideagent.ai/blends/glow- HTML link
<a href="https://peptideagent.ai/blends/glow">GLOW peptide: what is in it and does it work?</a>, PeptideAgent, updated October 28, 2026.